Literature DB >> 2548712

Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II.

J Markovits1, C Linassier, P Fossé, J Couprie, J Pierre, A Jacquemin-Sablon, J M Saucier, J B Le Pecq, A K Larsen.   

Abstract

Tyrosine phosphorylation plays a crucial role in cell proliferation and cell transformation which suggests that tyrosine kinase-specific inhibitors might be used as anticancer agents. When the cytotoxic effect of the potent tyrosine kinase inhibitor genistein on various cell lines was studied, we observed that 9-hydroxyellipticine-resistant Chinese hamster lung cells (DC-3F/9-OH-E) were markedly more resistant to genistein than the parental cell line (DC-3F). The DC-3F/9-OH-E cells have been shown to have an altered DNA topoisomerase II activity. We therefore examined the effects of genistein on DNA topoisomerase II-related activities of nuclear extracts from DC-3F cells as well as on purified DNA topoisomerase II from calf thymus. Our results show that genistein (a) inhibits the decatenation activity of DNA topoisomerase II and (b) stimulates DNA topoisomerase II-mediated double strand breaks in pBR322 DNA on sites different from those of 4'-(9-acridinylamino)methanesulfon-m-anisidide, etoposide, and 2-methyl-9-hydroxyellipticinium. Structure-activity studies with six chemically related compounds show that only genistein has an effect on the cleavage activity of DNA topoisomerase II in the concentration range studied. Finally, genistein treatment of DC-3F cells results in the occurrence of protein-linked DNA strand breaks as shown by DNA filter elution. Viscometric (lengthening) studies demonstrate that genistein is not a DNA intercalator. Genistein is therefore an interesting compound because it induces cleavable complexes without intercalation. Taken together, our results show that genistein is an inhibitor of both protein tyrosine kinases and mammalian DNA topoisomerase II. This could be accounted for by the sharing of a common structure sequence between the two proteins at the ATP binding site.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2548712

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  80 in total

Review 1.  Oral oncoprevention by phytochemicals - a systematic review disclosing the therapeutic dilemma.

Authors:  Sujana Mulk Bhavana; Chintamaneni Raja Lakshmi
Journal:  Adv Pharm Bull       Date:  2014-08-25

2.  Differential uptake of DNA-poly(ethylenimine) polyplexes in cells cultured on collagen and fibronectin surfaces.

Authors:  Anandika Dhaliwal; Maricela Maldonado; Zenas Han; Tatiana Segura
Journal:  Acta Biomater       Date:  2010-04-03       Impact factor: 8.947

3.  Activities and response to DNA damage of latent and active sequence-specific DNA binding forms of mouse p53.

Authors:  Y Wu; H Huang; Z Miner; M Kulesz-Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

4.  Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative.

Authors:  P Fossé; B René; M Le Bret; C Paoletti; J M Saucier
Journal:  Nucleic Acids Res       Date:  1991-06-11       Impact factor: 16.971

5.  Effects of selenite and genistein on G2/M cell cycle arrest and apoptosis in human prostate cancer cells.

Authors:  Rui Zhao; Nong Xiang; Fredrick E Domann; Weixiong Zhong
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

Review 6.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

7.  Inhibitory effect of tyrphostin on the replication of herpes simplex virus type 1.

Authors:  Y Yura; J Kusaka; Y Kondo; H Tsujimoto; H Yoshida; M Sato
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

8.  Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway.

Authors:  El-Shaimaa A Arafa; Qianzheng Zhu; Bassant M Barakat; Gulzar Wani; Qun Zhao; Mohamed A El-Mahdy; Altaf A Wani
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

9.  Proteolytic degradation of topoisomerase II (Top2) enables the processing of Top2·DNA and Top2·RNA covalent complexes by tyrosyl-DNA-phosphodiesterase 2 (TDP2).

Authors:  Rui Gao; Matthew J Schellenberg; Shar-Yin N Huang; Monica Abdelmalak; Christophe Marchand; Karin C Nitiss; John L Nitiss; R Scott Williams; Yves Pommier
Journal:  J Biol Chem       Date:  2014-05-07       Impact factor: 5.157

10.  Genistein inhibition of topoisomerase IIalpha expression participated by Sp1 and Sp3 in HeLa cell.

Authors:  Najing Zhou; Yunli Yan; Wenling Li; Yanling Wang; Lifen Zheng; Shuo Han; Yongxin Yan; Yunzhi Li
Journal:  Int J Mol Sci       Date:  2009-07-22       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.